Additional Biologic Therapeutics

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Biologic therapy for atopic dermatitis and allergic conditions represents a rapidly developing area of research development and clinical investigation in dermatology. Dupilumab, a biologic that blocks both interleukin (IL)-4 and IL-13 signaling, is the first biologic approved by the Food and Drug Administration for the treatment of atopic dermatitis. Omalizumab, which binds free immunoglobulin (Ig)E, was first used to treat asthma and was subsequently approved for patients with refractory chronic idiopathic urticaria. In this chapter, dupilumab and omalizumab and their applications within dermatology are reviewed in detail. This chapter also highlights several emerging biologic therapeutics within the field of dermatology.

Original languageEnglish (US)
Title of host publicationComprehensive Dermatologic Drug Therapy, Fourth Edition
PublisherElsevier
Pages339-348.e4
ISBN (Electronic)9780323612111
ISBN (Print)9780323612128
DOIs
StatePublished - Jan 1 2020

Keywords

  • anaphylaxis
  • atopic dermatitis
  • chronic idiopathic urticaria
  • dupilumab
  • IL-4 receptor
  • immunoglobulin E (IgE)
  • interleukin-13 (IL-13)
  • interleukin-4 (IL-4)
  • monoclonal antibody
  • omalizumab

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Additional Biologic Therapeutics'. Together they form a unique fingerprint.

Cite this